Trial Profile
A randomized open-label study to compare the safety and efficacy of conversion from a calcineurin inhibitor to sirolimus vs continued use of a calcineurin inhibitor in heart transplant recipients with mild-moderate impaired renal function
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Calcineurin inhibitors; Ciclosporin; Tacrolimus
- Indications Heart transplant rejection
- Focus Therapeutic Use
- Sponsors Wyeth
- 09 Jul 2012 Results published in the American Journal of Transplantation.
- 04 May 2011 Results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
- 16 Apr 2011 Results presented at the 31st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.